INTRAVITREOUS INJECTION OF BEVACIZUMAB, TISSUE PLASMINOGEN ACTIVATOR, AND GAS IN THE TREATMENT OF SUBMACULAR HEMORRHAGE IN AGE-RELATED MACULAR DEGENERATION

Abstract

From our retrospective pilot study, there is a strong indication that the addition of intravitreal bevacizumab is safe and superior to the displacement of submacular hemorrhages alone with rTPA and gas.